DTCFF (Defence Therapeutics) Other Financing: $-0.12 Mil (TTM As of Mar. 2026)


DTCFF Defence Therapeutics Inc DTCFF
21 GF Score
Price $0.35
! 1 Warning Sign
View Full Analysis

What is Defence Therapeutics Other Financing?

Defence Therapeutics DTCFF -2.02% 21 Other Financing is $-0.12 Mil as of Mar. 2026. GuruFocus rates DTCFF with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

Defence Therapeutics's Other Financing for the three months ended in Mar. 2026 was $0.00 Mil.

Defence Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.12 Mil.

Defence Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Defence Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Defence Therapeutics Other Financing Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Financing
Get a 7-Day Free Trial 2.55 0.00 -0.45 -0.09 -0.20

Defence Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.76 -0.01 -0.12 0.00 0.00
DTCFF
21GF Score
Defence Therapeutics Inc DTCFF
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Defence Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-0.12 Mil mean?
Defence Therapeutics (DTCFF) has a Other Financing of $-0.12 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Defence Therapeutics and its competitors.
Is Defence Therapeutics' Other Financing too high?
Defence Therapeutics' current Other Financing is $-0.12 Mil. Overall, Defence Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Defence Therapeutics' Other Financing compare to VRTX and REGN?
Defence Therapeutics' Other Financing of $-0.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Defence Therapeutics and its competitors. Defence Therapeutics's current Other Financing is $-0.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Defence Therapeutics stock overvalued right now?
Defence Therapeutics (DTCFF) has a current Other Financing of $-0.12 Mil. The current Other Financing is $-0.12 Mil. Defence Therapeutics' overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Defence Therapeutics (DTCFF), the current Other Financing is $-0.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Defence Therapeutics Business Description

Other Exchanges DTC:GermanyDTC:Canada
Address 7171 Frederick Banting Street, Montreal, QC, CAN, H4S 1Z9
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development. It operates only in Canada.
21GF Score

Get the complete analysis for DTCFF

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price